IL143299A0 - Pharmaceutical composition comprising 5-[[4- [3-methyl-4-oxo-3, 4-dihydro-2-quinazolinyl] methoxy] phenyl-methyl] thiadiazolidine-2, 4-dione and the process for its preparation - Google Patents

Pharmaceutical composition comprising 5-[[4- [3-methyl-4-oxo-3, 4-dihydro-2-quinazolinyl] methoxy] phenyl-methyl] thiadiazolidine-2, 4-dione and the process for its preparation

Info

Publication number
IL143299A0
IL143299A0 IL14329999A IL14329999A IL143299A0 IL 143299 A0 IL143299 A0 IL 143299A0 IL 14329999 A IL14329999 A IL 14329999A IL 14329999 A IL14329999 A IL 14329999A IL 143299 A0 IL143299 A0 IL 143299A0
Authority
IL
Israel
Prior art keywords
methyl
thiadiazolidine
quinazolinyl
dione
dihydro
Prior art date
Application number
IL14329999A
Other languages
English (en)
Original Assignee
Novo Nordisk As
Reddy Research Foundation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novo Nordisk As, Reddy Research Foundation filed Critical Novo Nordisk As
Publication of IL143299A0 publication Critical patent/IL143299A0/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Diabetes (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Endocrinology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
IL14329999A 1998-12-01 1999-11-29 Pharmaceutical composition comprising 5-[[4- [3-methyl-4-oxo-3, 4-dihydro-2-quinazolinyl] methoxy] phenyl-methyl] thiadiazolidine-2, 4-dione and the process for its preparation IL143299A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DKPA199801580 1998-12-01
PCT/DK1999/000663 WO2000032191A1 (en) 1998-12-01 1999-11-29 New pharmaceutical composition and the process for its preparation

Publications (1)

Publication Number Publication Date
IL143299A0 true IL143299A0 (en) 2002-04-21

Family

ID=8106261

Family Applications (3)

Application Number Title Priority Date Filing Date
IL14329999A IL143299A0 (en) 1998-12-01 1999-11-29 Pharmaceutical composition comprising 5-[[4- [3-methyl-4-oxo-3, 4-dihydro-2-quinazolinyl] methoxy] phenyl-methyl] thiadiazolidine-2, 4-dione and the process for its preparation
IL143299A IL143299A (en) 1998-12-01 2001-05-22 Pharmaceutical preparation containing 5 - [[- [3-methyl - 4 - oxo - 3,4 - dehydro - quinazolinyl] methoxy] phenyl-methyl] thiadiazolidine - 2,4 - deion and process for its preparation
IL179865A IL179865A (en) 1998-12-01 2006-12-05 Pharmaceutical composition comprising 5 - [[4-[3 - methyl- 4- oxo - 3,4 - dihydro - 2 - quinazolinyl]methoxy] phenyl-methyl]thiadiazolidine-2,4- dione in the form of a tablet, a powder or a capsule and process for its preparation

Family Applications After (2)

Application Number Title Priority Date Filing Date
IL143299A IL143299A (en) 1998-12-01 2001-05-22 Pharmaceutical preparation containing 5 - [[- [3-methyl - 4 - oxo - 3,4 - dehydro - quinazolinyl] methoxy] phenyl-methyl] thiadiazolidine - 2,4 - deion and process for its preparation
IL179865A IL179865A (en) 1998-12-01 2006-12-05 Pharmaceutical composition comprising 5 - [[4-[3 - methyl- 4- oxo - 3,4 - dihydro - 2 - quinazolinyl]methoxy] phenyl-methyl]thiadiazolidine-2,4- dione in the form of a tablet, a powder or a capsule and process for its preparation

Country Status (21)

Country Link
US (1) US7439248B1 (cs)
EP (1) EP1135127B1 (cs)
JP (2) JP5524435B2 (cs)
KR (1) KR100690311B1 (cs)
CN (1) CN1158075C (cs)
AT (1) ATE316376T1 (cs)
AU (1) AU776299B2 (cs)
BR (1) BR9915835A (cs)
CA (1) CA2352430C (cs)
CZ (1) CZ300543B6 (cs)
DE (1) DE69929635T2 (cs)
ES (1) ES2257886T3 (cs)
HU (1) HUP0104544A3 (cs)
IL (3) IL143299A0 (cs)
NO (1) NO329909B1 (cs)
PL (1) PL197077B1 (cs)
RU (1) RU2233659C2 (cs)
TW (1) TWI235657B (cs)
UA (1) UA75569C2 (cs)
WO (1) WO2000032191A1 (cs)
ZA (1) ZA200104261B (cs)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5524435B2 (ja) * 1998-12-01 2014-06-18 ドクター レディーズ ラボラトリーズ リミティド 新規医薬組成物及びその調製のための方法
US20010047032A1 (en) * 1999-12-30 2001-11-29 Castillo Gerardo M. Polyhydroxylated aromatic compounds for the treatment of amyloidosis and alpha-synuclein fibril diseases
WO2001091751A1 (en) * 2000-05-30 2001-12-06 Novo Nordisk A/S New pharmaceutical composition and the process for its preparation
WO2001089523A1 (en) 2000-05-26 2001-11-29 Novo Nordisk A/S New pharmaceutical composition and the process for its preparation
AU2002366313A1 (en) * 2001-12-19 2003-06-30 Takeda Chemical Industries, Ltd. Solid compositions containng compounds unstable to oxygen and method for stabilization thereof
US7514552B2 (en) * 2003-05-30 2009-04-07 Asahi Kasei Chemicals Corporation Cellulose powder
WO2006002255A2 (en) * 2004-06-23 2006-01-05 Dr. Reddy's Laboratories Ltd. A pharmaceutical formulation of balaglitazone
CL2008000596A1 (es) * 2007-03-01 2008-09-05 Glaxo Group Ltd Forma de dosificacion que comprende 1-(6-[(3-ciclobutil-2,3,4,5-tetrahidro-1h-3-benzazepin-7-il)oxi]-3-piridinil)-2-pirrolidinona, un estabilizador, un excipiente; procedimiento de preparacion; y su uso para tratar enfermedades neurologicas.

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4280997A (en) * 1978-12-08 1981-07-28 Johannes Van Leverink Extrusion process for the preparation of anhydrous stable lactose
DE3433239A1 (de) * 1984-09-11 1986-03-20 Bayer Ag, 5090 Leverkusen Feste arzneizubereitung enthaltend nitrendipin und verfahren zu ihrer herstellung
US5330998A (en) * 1988-03-08 1994-07-19 Pfizer Inc. Thiazolidinedione derivatives as hypoglycemic agents
CA2019324C (en) * 1989-07-10 1996-08-20 Robert L. Jerzewski Fosinopril tablet formulations
FR2656610B1 (fr) * 1989-12-29 1992-05-07 Sanofi Sa Derives d'amino-2 phenyl-4 thiazole, leur procede de preparation et leur application therapeutique.
IT1238072B (it) * 1990-01-19 1993-07-03 Sclavo Spa Composizioni farmaceutiche e forme di dosaggio per la somministrazione orale di calcitonina
CA2106216C (en) * 1991-04-04 1997-06-10 Paul Randolph Court Chewable antacid compositions
SK117793A3 (en) * 1991-04-29 1994-05-11 Merck & Co Inc Optimized tablet formulation
TW245716B (cs) * 1992-12-28 1995-04-21 Takeda Pharm Industry Co
TW268952B (cs) * 1993-02-26 1996-01-21 Takeda Pharm Industry Co Ltd
WO1994022857A1 (fr) * 1993-04-07 1994-10-13 Taiho Pharmaceutical Co., Ltd. Derive de thiazolidine et composition pharmaceutique contenant ce derive
ES2185666T3 (es) * 1993-09-03 2003-05-01 Smithkline Beecham Corp Formulacion estabilizada para comprimidos.
US5457109A (en) * 1993-09-15 1995-10-10 Warner-Lambert Company Use of thiazolidinedione derivatives and related antihyperglycemic agents in the treatment of disease states at risk for progressing to noninsulin-dependent diabetes mellitus
US5532256A (en) 1994-05-18 1996-07-02 American Home Products Corporation New azolidinediones and thiadiazolidinediones as antihyperglycemic agents
ES2079327B1 (es) * 1994-12-13 1996-08-01 Lilly Sa Formulaciones farmaceuticas de cefaclor.
WO1996018386A1 (en) * 1994-12-14 1996-06-20 Enbalt Trading Limited Pharmaceutical tablet formulations for direct compression
US6395303B1 (en) * 1996-06-10 2002-05-28 Edward Mendell Co., Inc. Process for preparing a directly compressible solid dosage form containing microcrystalline cellulose
JPH09249561A (ja) * 1996-03-15 1997-09-22 Teikoku Chem Ind Corp Ltd 医薬組成物
HU222109B1 (hu) * 1996-09-10 2003-04-28 EGIS Gyógyszergyár Rt. Captopriltartalmú tabletták és eljárás ezek előállítására
RU2200161C2 (ru) * 1996-12-31 2003-03-10 Др. Редди'З Рисерч Фаундейшн Новые производные азолидиндиона, способ их получения (варианты), фармацевтические композиции на их основе, способ предупреждения или лечения, способ снижения глюкозы и промежуточное соединение
EP1036075B1 (en) 1997-12-02 2004-06-23 Dr. Reddy's Laboratories Ltd. Substituted thiazolidinedione and oxazolidinedione having antidiabetic, hypolipidemia and antihypertensive properties
EP0945134A1 (de) * 1998-03-27 1999-09-29 Boehringer Ingelheim Pharma KG Neue galenische Zubereitungsformen von Meloxicam zur oralen Applikation
JP5524435B2 (ja) * 1998-12-01 2014-06-18 ドクター レディーズ ラボラトリーズ リミティド 新規医薬組成物及びその調製のための方法
WO2001089523A1 (en) * 2000-05-26 2001-11-29 Novo Nordisk A/S New pharmaceutical composition and the process for its preparation
WO2006002255A2 (en) 2004-06-23 2006-01-05 Dr. Reddy's Laboratories Ltd. A pharmaceutical formulation of balaglitazone

Also Published As

Publication number Publication date
CZ300543B6 (cs) 2009-06-10
PL348601A1 (en) 2002-06-03
NO20012673D0 (no) 2001-05-31
KR100690311B1 (ko) 2007-03-09
EP1135127B1 (en) 2006-01-25
HUP0104544A2 (en) 2002-08-28
CA2352430A1 (en) 2000-06-08
ATE316376T1 (de) 2006-02-15
DE69929635T2 (de) 2006-09-21
AU1376200A (en) 2000-06-19
JP2002531404A (ja) 2002-09-24
EP1135127A1 (en) 2001-09-26
AU776299B2 (en) 2004-09-02
NO20012673L (no) 2001-05-31
WO2000032191A1 (en) 2000-06-08
PL197077B1 (pl) 2008-02-29
NO329909B1 (no) 2011-01-24
UA75569C2 (en) 2006-05-15
CN1356901A (zh) 2002-07-03
CZ20011832A3 (cs) 2001-10-17
ES2257886T3 (es) 2006-08-01
HUP0104544A3 (en) 2003-12-29
IL179865A0 (en) 2007-05-15
IL179865A (en) 2009-12-24
JP2012144560A (ja) 2012-08-02
CA2352430C (en) 2008-11-18
KR20010099827A (ko) 2001-11-09
TWI235657B (en) 2005-07-11
CN1158075C (zh) 2004-07-21
JP5524435B2 (ja) 2014-06-18
BR9915835A (pt) 2001-08-21
DE69929635D1 (de) 2006-04-13
RU2233659C2 (ru) 2004-08-10
IL143299A (en) 2006-12-31
US7439248B1 (en) 2008-10-21
ZA200104261B (en) 2002-05-24

Similar Documents

Publication Publication Date Title
HUP0203841A3 (en) 5-membered heteroaromatic compounds and use thereof for preparation of pharmaceutical compositions, and pharmaceutical compositions containing them
WO2000017190A3 (fr) Derives d'amidines, leur preparation, leur application a titre de medicaments et les compositions pharmaceutiques les contenant
HUP0202682A3 (en) Tyrosine kinase inhibitors, pharmaceutical compositions containing them and their use
AU2001236457A1 (en) Compounds and compositions for delivering active agents
HUP0200355A3 (en) 4-aminopyrrolopyrimidines as kinase inhibitors, pharmaceutical compositions containing them and their use
HUP0203403A3 (en) New imidazole derivatives, pharmaceutical compositions containing them and their use
WO2000057900A3 (en) Factor for regulation of neurite growth
ZA200206905B (en) Azetidine derivatives, preparation thereof and pharmaceutical compositions containing same.
AU2001237525A1 (en) Azetidine derivatives, preparation thereof and pharmaceutical compositions containing same
HUP0203902A3 (en) Substituted oxazolidinones, process for their preparation and pharmaceutical compositions containing them and their use
HUP0103283A3 (en) Pyrazinone protease inhibitors, pharmaceutical compositions containing them and use of the compounds
IL158168A0 (en) 5-membered, nitrogen-containing heterocyclic compounds and pharmaceutical compositions containing the same
HUP0400908A3 (en) Pyrazole compounds useful as protein kinase inhibitors, their use and pharmaceutical compositions containing them
AU2001284985A1 (en) Compounds and compositions for delivering active agents
HUP0202520A3 (en) Substituted benzylthiazolidine-2,4-dione derivatives and pharmaceutical compositions containing them
HUP0400832A3 (en) New amidoalkyl-piperidine and amidoalkyl-piperazine derivatives, and pharmaceutical compositions containing such derivatives as active ingredients
IL156662A0 (en) Oxazolidinone derivatives, process for the preparation thereof and pharmaceutical compositions containing the same
AU2002333373A1 (en) Combined preparations, containing 1,4-benzothiepine-1,1-dioxide derivatives and other active substances, and the use thereof
HRP20040171A2 (en) Combined preparations, containing 1,4-benzothiepine-1,1-dioxide derivatives and other active substances, and the use thereof
AU2001228811A1 (en) Nitrogen-containing 5-membered cyclic compounds and drugs containing these compounds as the active ingredient
HUP0202701A3 (en) Substituted benzylthiazolidine-2,4-dione derivatives and pharmaceutical compositions containing them
HUP0202893A3 (en) Substituted benzylthiazolidine-2,4-dione derivatives and pharmaceutical compositions containing them
AU2001288277A1 (en) Compounds and compositions for delivering active agents
AU2001268131A1 (en) Stabilized compositions containing oxygen-labile active agents
HUP0303636A3 (en) Dihydronaphthalenederivative compounds and pharmaceutical compositions containing them as active ingredient

Legal Events

Date Code Title Description
FF Patent granted
KB Patent renewed